The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
La Food and Drug Administration (FDA) des États-Unis a accordé une autorisation accélérée au tarlatamab, l'immunothérapie ciblée d'Amgen, pour le traitement des adultes atteints d'un cancer ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
La Food and Drug Administration (FDA) des États-Unis a accordé jeudi une autorisation accélérée au nouveau médicament d'Amgen (AMGN), le tarlatamab, commercialisé sous le nom de marque Imdelltra, pour ...
FRIDAY, May, 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has published its report on new drug approvals in 2022, Advancing Health Through Innovation: New Drug Therapy ...
Vendredi, les analystes d'Oppenheimer ont maintenu les perspectives positives d' Amgen Inc . (NASDAQ:AMGN), avec une réitération de la note "Outperform" et un objectif de prix stable de 380,00 $. Cet ...
Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
AbbVie ABBV dosed the first patient with ABBV-383, an investigational BCMA-CD3-targeted bispecific antibody, in the phase III ...